About Hyperion

Hyperion Therapeutics, Inc. is a privately held specialty biopharmaceutical company dedicated to improving patients’ lives through the development and commercialization of therapies that address critical unmet needs and underserved patient populations. The Company was founded in 2006 and is focused in the areas of gastroenterology and hepatology.

Hyperion aims to build a portfolio of products through partnership, in-licensing, and/or internal development efforts. In August, 2007, through a strategic collaboration with Ucyclyd Pharma, Inc. (a subsidiary of Medicis Pharmaceutical Corporation), Hyperion obtained sales and marketing responsibilities for the only two FDA-approved medications indicated as adjunctive therapy in the management of urea cycle disorders (UCDs): AMMONUL^® (sodium phenylacetate/sodium benzoate) Injection 10%/10% and BUPHENYL^® (sodium phenylbutyrate). As part of this agreement, Hyperion is also continuing the research and development of HPN-100 (formerly known as GT4P) for urea cycle disorders (UCD) and hepatic encephalopathies (HE), and AMMONUL^® (sodium phenylacetate/sodium benzoate) Injection 10%/10% for HE. If these products and uses are approved by the FDA, Hyperion will commercialize them as well.

Hyperion is led by a seasoned executive team with extensive experience developing and commercializing specialty pharmaceutical products. The Company is backed by Sofinnova Ventures, NEA, Highland Capital Partners and WRF Capital.

Click here for key safety information for AMMONUL^®
Click here for full prescribing information for AMMONUL^®

Click here for key safety information for BUPHENYL^®
Click here for full prescribing information for BUPHENYL^®

AMMONUL and BUPHENYL are registered trademarks of Ucyclyd Pharma, Inc.